Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Krassnig, S; Leber, SL; Orthmann, A; Golob-Schwarzl, N; Huber, HJ; Wohlrab, C; Skofler, C; Pennauer, M; Raicht, A; Birkl-Toeglhofer, AM; Naumann, M; Mahdy-Ali, K; von, Campe, G; Leoni, M; Alcaniz, J; Hoffmann, J; Wälchli, T; Weis, S; Benesch, M; Haybaeck, J.
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
J Neurooncol. 2023; 165(1):91-100
Doi: 10.1007/s11060-023-04451-y
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Haybäck Johannes
- Kraßnig Stefanie
- Leber Stefan
- Co-authors Med Uni Graz
- Benesch Martin
- Birkl-Töglhofer Anna Maria
- Golob-Schwarzl Nicole
- Leoni Marlene
- Raicht Andrea
- Skofler Christina
- von Campe Gord
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: Since glioma therapy is currently still limited until today, new treatment options for this heterogeneous group of tumours are of great interest. Eukaryotic initiation factors (eIFs) are altered in various cancer entities, including gliomas. The purpose of our study was to evaluate the potential of eIFs as novel targets in glioma treatment. METHODS: We evaluated eIF protein expression and regulation in 22 glioblastoma patient-derived xenografts (GBM PDX) after treatment with established cytostatics and with regards to mutation profile analyses of GBM PDX. RESULTS: We observed decreased expression of several eIFs upon temozolomide (TMZ) treatment independent from the phosphatidylinositol 3-kinase (PI3K)/ AKT/ mammalian target of the rapamycin (mTOR) signalling pathway. These effects of TMZ treatment were not present in TMZ-resistant PDX. Combination therapy of regorafenib and TMZ re- established the eIF/AKT/mTOR axis. CONCLUSION: Our study provides novel insights into chemotherapeutic effects on eIF regulation in gliomas and suggests that eIFs are interesting candidates for future research to improve glioma therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Temozolomide - therapeutic use, pharmacology
- Proto-Oncogene Proteins c-akt - metabolism
- Phosphatidylinositol 3-Kinases - metabolism
- Dacarbazine - therapeutic use, pharmacology
- Brain Neoplasms - genetics
- Cell Line, Tumor - administration & dosage
- Glioma - drug therapy, pathology
- Glioblastoma - drug therapy, pathology
- TOR Serine-Threonine Kinases - metabolism
- Find related publications in this database (Keywords)
- Astrocytoma
- Glioma
- Eukaryotic initiation factors
- Temozolomide
- Glioma therapy